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Sensitization of Melanoma Cells for Death Ligand
TRAIL Is Based on Cell Cycle Arrest, ROS Production,
and Activation of Proapoptotic Bcl-2 Proteins
Sandra-Annika Quast1, Katja Steinhorst1, Michael Plötz1 and Jürgen Eberle1
The death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) represents a promising strategy
for melanoma due to signiﬁcant expression of TRAIL receptor 1 in melanoma metastases and high TRAIL
sensitivity through this receptor. However, prevalent and inducible resistance are limiting its clinical use. In
previous work, we and others have described multiple strategies leading to TRAIL sensitization; however, the
common principles of these strategies remained elusive. Here, we demonstrate in melanoma cell lines (TRAIL-
sensitive, TRAIL-resistant, and TRAIL-selected cells with acquired resistance) that cell cycle arrest clearly
correlates with enhanced TRAIL sensitivity. Cell cycle arrest was induced by high cell conﬂuence, serum
starvation, or cyclin-dependent kinase (CDK) 4/6 inhibition. Addressing the signaling pathways revealed
disruption of mitochondrial membrane potential and production of reactive oxygen species (ROS) in response to
antiproliferative conditions alone. Activation of the proapoptotic Bcl-2 protein Bax and inhibition of apoptosis by
Bcl-2 overexpression or by the antioxidant N-acetyl cysteine underlined the critical involvement of mitochondrial
apoptosis pathways and of ROS, respectively. Most pronounced was the upregulation of small proapoptotic Bcl-2
proteins (Puma and Bcl-xS). These data provide a general understanding on TRAIL sensitization as well as an
alternative view on CDK inhibitors and may suggest selective targeting of melanoma cells by cell cycle inhibition
and TRAIL.
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INTRODUCTION
Despite recent development of improved therapeutic strate-
gies, long-term prognosis of metastatic melanoma remains
fatal. Direct apoptosis induction appears as an alternative,
and TRAIL (tumor necrosis factor-related apoptosis-inducing
ligand) is considered as it allows a selective targeting of
cancer cells (Walczak et al., 1999; Ashkenazi, 2002; Eberle
et al., 2007). TRAIL works via TRAIL receptors 1 and 2 (DR4
and DR5), and we previously demonstrated DR4 expression
in melanoma metastases and high sensitivity through this
receptor (Kurbanov et al., 2007).
Apoptosis induction is explained by two major signaling
pathways. Whereas extrinsic pathways are initiated by death
ligands triggering activation of death receptors and initiator
caspases-8 and -10 (Krammer et al., 2007), intrinsic
mitochondrial apoptosis pathways result from cellular stress
as by chemotherapeutics. Characteristic features are
depolarization of mitochondrial membrane potential (Δψm),
release of mitochondrial factors and activation of initiator
caspase-9 (Jin and El-Deiry, 2005). Initiator caspases activate
effector caspase-3, which irreversibly triggers cell death
(Fischer et al., 2003).
Mitochondrial apoptosis is critically controlled by Bcl-2
proteins, as antiapoptotic Bcl-2, Mcl-1, and Bcl-xL, proapop-
totic multidomain proteins Bax and Bak, proapoptotic
BH3-only proteins as Bim and Puma, as well as proapoptotic
Bcl-xS, an alternative splice form of Bcl-xL (Chipuk et al.,
2010; Tait and Green, 2010; Plötz et al., 2012). Bax activation
can be monitored by conformational changes detectable
by N-terminus-speciﬁc antibodies (Westphal et al., 2011),
and Bax activation was shown to precede sensitization of
melanoma cells for TRAIL (Berger et al., 2013; Quast et al.,
2013). Other proapoptotic pathways are related to the
production of reactive oxygen species (ROS; Orrenius,
2007), which appeared as particularly effective in
melanoma cells (Franke et al., 2010; Quast et al., 2013).
In clinical trials, the effects of TRAIL remained rather
limited so far, explained by an inducible resistance (Herbst
et al., 2010; Soria et al., 2011). This is also seen in cultured
melanoma cells, and TRAIL-selected cell lines have been
established (Zhang et al., 2006; Kurbanov et al., 2007).
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Addressing resistance, different strategies were described that
could sensitize for TRAIL. Thus for melanoma, inhibitors of
several kinases, potassium channels, histone deacetylase,
cyclooxygenase 2, natural and inorganic compounds, or
irradiation were effective, as recently reviewed (Quast et al.,
2014). Because of the highly different nature of these
strategies, the common principles of TRAIL sensitization
remained largely elusive.
Growth of normal cells is tightly regulated by cyclins and
cyclin-dependent kinases (CDKs; Canavese et al., 2012;
Miller and Flaherty, 2014), which are frequently deregulated
in cancer (Hanahan and Weinberg, 2011). Cell cycle
inhibition therefore represents an important target in cancer
therapy. Here, we demonstrate the correlation between cell
cycle inhibition and TRAIL sensitivity, suggesting therapeutic
strategies by combining CDK inhibitors and TRAIL.
RESULTS
Enhanced sensitivity to TRAIL strongly correlates with cell cycle
arrest
For understanding common principles how melanoma cells
are sensitized for TRAIL-induced apoptosis, inhibition of cell
proliferation was induced by cell conﬂuence, serum starva-
tion, or CDK4/6 inhibition. TRAIL-sensitive cell lines (A-375,
SK-Mel-13, and Mel-HO) responded to TRAIL with 4–18%
apoptosis at normal seeding (LD, low density: 50–60%
conﬂuence, Figure 1a). In contrast, TRAIL was inefﬁcient in
TRAIL-selected cells (A-375-TS and SK-Mel-13-TS) and in
intrinsically TRAIL-resistant cell lines (MeWo and Mel-2a).
Seeding in high density (HD: 100% conﬂuence at treatment)
signiﬁcantly enhanced TRAIL-induced apoptosis in sensitive
A-375, SK-Mel-13, and Mel-HO (43, 22, and 11%), as well as
in A-375-TS and SK-Mel-13-TS (19 and 12%; Figure 1a). Of
note, enhanced sensitivity clearly correlated with G1 cell cycle
arrest and reduced cell numbers in G2 (Figure 1b and c).
Only intrinsically resistant cells MeWo and Mel-2a were
not sensitized by HD alone. However, further strengthening
the antiproliferative conditions by combination of HD and
serum deprivation similarly enhanced TRAIL-induced apop-
tosis in these cells (14–16%). Also in Mel-HO, strongest
enhancement of apoptosis (23%) was seen by this combina-
tion (Figure 1d). Enhanced sensitivity again correlated with
G1 cell cycle arrest (Figure 1e and f).
Proapoptotic activation of caspases, mitochondria, and Bax
For unravelling the pathways mediating enhanced TRAIL
sensitivity, caspase activation was investigated by Western
blotting. In A-375, some activation (processing) of caspase-8
(41, 43 kDa), caspase-9 (35, 37 kDa), and caspase-3 (15, 17,
20 kDa) was seen by TRAIL at LD conditions, which was
lacking in A-375-TS. Caspase processing was strongly
enhanced at HD in both cell lines (Figure 2a). The role of
caspases was proven by the pancaspase inhibitor Q-VD-OPh,
which completely prevented TRAIL-induced apoptosis at LD
and HD in A-375 and in A-375-TS (Figure 2b). To distinguish
between initial and secondary effects in course of apoptosis,
time kinetic analyses were performed. Apoptosis induction by
TRAIL started at 6–8 hours at HD and LD, respectively
(Figure 2c), which came clearly after the effects shown in
the following.
Indicative for proapoptotic mitochondrial pathways, Δψm
was signiﬁcantly decreased at HD in A-375, A-375-TS, Mel-
HO, Mel-2a, and MeWo. It further decreased at HD/− FCS
(fetal calf serum), in parallel with enhanced apoptosis (Figure
2d and e). Of note, this happened as a consequence of the
antiproliferative conditions alone (without TRAIL-induced
apoptosis).
Bax was shown previously to exert decisive roles in
regulating TRAIL sensitivity of melanoma cells (Quast et al.,
2014). Signiﬁcant Bax activation, as determined by an
N-terminus-speciﬁc antibody, was seen in A-375 and in
A-375-TS at HD conditions, as well as in Mel-HO, Mel-2a,
and MeWo at HD/–FCS conditions (Figure 2f and g).
ROS production
We previously demonstrated the role of ROS in apoptosis
control of melanoma cells (Franke et al., 2010; Quast et al.,
2013). ROS levels were clearly increased in A-375, A-375-TS,
and Mel-HO in response to HD conditions. In contrast, TRAIL
largely remained without effect on ROS despite in A-375 at
HD, when high ROS levels were further enhanced by TRAIL
(1.4-fold). ROS were also enhanced by serum deprivation in
Mel-HO, and strongest effects were seen at HD/− FCS (Figure
3a and b). Thus, ROS were produced in response to
antiproliferative conditions.
The critical role of ROS was proven by the ROS scavenger
N-acetyl cysteine. Pretreatment for 2 hours with N-acetyl
cysteine completely prevented ROS production at HD in
A-375 and Mel-HO (Figure 3c and d) and reduced TRAIL-
induced apoptosis at HD by 5.1-fold in A-375 and by 2.8-fold
in Mel-HO (Figure 3e).
Enhanced TRAIL sensitivity by CDK4/6 inhibition
The critical role of cell cycle inhibition for TRAIL sensitivity
was further proven in A-375, A-375-TS, Mel-HO, Mel-2a, and
MeWo by the CDK4/6 inhibitor PD-0332991. Alone, it
remained without effect on apoptosis at 24 hours but strongly
enhanced TRAIL-induced apoptosis in A-375, Mel-HO, and
A-375-TS (43, 17 and 19%). Only in intrinsically resistant
Mel-2a and MeWo, apoptosis induction by TRAIL/CDK-I
remained moderate at +FCS (7% and 8%).
As serum starvation had enhanced cell cycle arrest by HD
in parallel with TRAIL sensitivity, it was close to test whether
lack of FCS could similarly support CDK inhibition. Indeed,
TRAIL sensitivity was signiﬁcantly enhanced by CDK-I/− FCS
in Mel-2a, MeWo, and Mel-HO (15, 16, and 32%; Figure 4a).
G1 cell cycle arrest seen in all cells already by CDK inhibition
was even more pronounced after additional serum depriva-
tion (Figure 4b). There was a signiﬁcant correlation between
cell cycle arrest and TRAIL sensitivity at different cell culture
conditions (correlation coefﬁcient for Mel-HO: 0.87; for
MeWo: 0.77).
CDK inhibition resulted in similar effects as seen before for
HD conditions. Thus, Δψm was reduced, and Bax was
signiﬁcantly activated in A-375 also by PD-0332991 at 4
hours (without TRAIL; Figure 4c and d). Only production of
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Figure 1. Induced cell cycle arrest correlates with enhanced TRAIL sensitivity. (a and d) Apoptosis (% of sub-G1 cells) was determined in seven melanoma
cell lines in response to TRAIL (20 ngml−1). Cells were seeded in low (LD) or high density (HD), as well as with or without fetal calf serum (FCS). Means and
SDs are of three independent experiments, each consisting of triplicates. Statistical signiﬁcance (*Po0.005) is indicated. (b and e) Corresponding histograms of
cell cycle analyses and % of cells in G1/G2 (mean values). (c and f) Quantitative cell cycle analyses show % of cells in G1/G2, corresponding to b and e.
Signiﬁcant changes are indicated by asterisks (Po0.05).
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Figure 2. Activation of caspases and mitochondria. (a) Processing of caspases-3, -9, and -8 in response to TRAIL (20 ngml−1) was monitored by Western blotting
in cells seeded in low density/high density (LD/HD; loading control: glyceraldehyde-3-phosphate dehydrogenase (GAPDH)). Two independent experiments
revealed comparable results. (b) Apoptosis (% of sub-G1 cells) in response to TRAIL and the pancaspase inhibitor Q-VD-OPh (QVD, 10 μM, 1 hour pretreatment).
(c) Time kinetic analyses of apoptosis induced by TRAIL (20 ngml−1) in A-375 at LD/HD. (d) Mitochondrial membrane potential (Δψm) was determined by
TMRM+ staining. (f) Bax activation was determined by Bax-NT antibody in cells at LD/HD± FCS (fetal calf serum). (e and g) Quantiﬁcation of Δψm and activated
Bax (each two independent experiments=6 values, means± SD). Rel, relative.
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ROS in response to PD-0332991 was less pronounced at
4 hours (Figure 4e).
Decisive roles of Bcl-2 and Mcl-1
The dominant role of Bcl-2 became evident by its ectopic
overexpression. Thus, TRAIL-induced apoptosis, seen in
mock-transfected controls (A-375-pIRES) at LD and HD, was
prevented in A-375-Bcl-2, stably transfected for Bcl-2 over-
expression (Figure 5a). Also, the G1 arrest induced by HD was
diminished by Bcl-2 (Figure 5b). The inhibitory function of
Mcl-1 was seen by Mcl-1 knockdown, which signiﬁcantly
increased TRAIL responsiveness in A-375 and A-375-TS both
at LD and HD (Figure 5c).
As parental cells, A-375-pIRES responded with signiﬁcant
loss of Δψm to different antiproliferative conditions, which
was strongly diminished by Bcl-2 overexpression (Figure 5d
and f) underlining the role of mitochondrial activation for
TRAIL sensitivity. In clear contrast, ROS production in
response to HD and HD/− FCS was not prevented by Bcl-2,
rather appeared as even enhanced (Figure 5e and g). This
suggested two independent pathways.
Upregulation of small proapoptotic Bcl-2 proteins
Mitochondrial proapoptotic activation was suggestive to
search for changes at the expression level of pro- and
antiapoptotic Bcl-2 proteins. No changes were obtained by
Western blotting for antiapoptotic Bcl-2, Mcl-1, and Bcl-xL or
for proapoptotic multidomain proteins Bax and Bak, when
comparing HD and LD conditions. However, when consider-
ing small proapoptotic Bcl-2 proteins, which may act as
triggers in apoptosis control, signiﬁcant changes became
obvious. Thus, the BH3-only protein Puma was signiﬁcantly
upregulated by HD conditions in A-375, A-375-TS, SK-Mel-
13, SK-Mel-13-TS, and Mel-HO. Also Bcl-xS, the proapoptotic
splice variant of Bcl-xL, was upregulated in SK-Mel-13 and
SK-Mel-13-TS by HD conditions, as well as in Mel-HO by
HD/− FCS conditions (Figure 6a).
The decisive role of Puma was proven by small interfering
RNA (siRNA) strategies. Thus, two distinct siRNA sequences
revealed identical results, namely complete knockdown of
Puma (Figure 6b), as well as a signiﬁcant reduction in TRAIL-
induced apoptosis at HD in A-375 and A-375-TS (Figure 6c).
Downregulation of apoptosis was 1.9- to 4.9-fold, thus clearly
underlining the role of Bcl-2 proteins in this response.
DISCUSSION
The death ligand TRAIL represents a promising therapeutic
strategy, as apoptosis is induced in a number of tumor cells
while normal cells are largely spared (Walczak et al., 1999;
Ashkenazi, 2002). Clinical trials have been carried out in non-
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Hodgkin’s lymphoma, non-small cell lung cancer, and in
patients with liver metastases of different origin (Herbst et al.,
2010; Younes et al., 2010; Soria et al., 2011). TRAIL should be
considered for melanoma because of signiﬁcant DR4
expression in melanoma metastasis and DR4-mediated TRAIL
sensitivity in melanoma cells (Kurbanov et al., 2005).
However, inducible and intrinsic TRAIL resistance were
reported in different cancer cell models and may explain
only limited clinical efﬁcacy (Graves et al., 2014). Thus, 30%
of melanoma cell lines reveal intrinsic resistance, whereas
TRAIL-sensitive cells may acquire resistance upon treatment
(Kurbanov et al., 2007).
Addressing this limitation, different strategies have been
reported for enhancing TRAIL sensitivity of tumor cells. In
melanoma, these enclosed multiple kinase inhibitors targeting
protein kinase C (Gillespie et al., 2005), c-Kit (Hamai et al.,
2006), inhibitor of NF-kappaB kinase/nuclear factor kappaB
(Berger et al., 2013), phosphatidylinositol 3-kinase/protein
kinase B (Quast et al., 2013), and mitogen-activated protein
kinases (Berger et al., 2014). Also, inhibitors of potassium
channels (Quast et al., 2012; Suzuki et al., 2012), cellular
metabolism (Liu et al., 2009; Qin et al., 2010), histone
deacetylase (Zhang et al., 2003), and cyclooxygenase 2 (Tse
et al., 2014) were effective as well as natural compounds as
picropodophyllin (Karasic et al., 2010), indirubin (Berger
et al., 2011), and cryptotanshinone (Tse et al., 2013) or
inorganic compounds as sodium arsenite (Ivanov and Hei,
2006; Ivanov and Hei, 2011). Because of this extremely high
diversity, the pathways of melanoma sensitization for TRAIL
remained elusive. The identiﬁcation of the common end
path would allow more selective targeting of cancer cells
by TRAIL.
Uncontrolled cell proliferation represents a hallmark of
cancer underlined by frequent mutations in cell cycle
regulators (Hanahan and Weinberg, 2011). The cell cycle is
regulated primarily at G1/S and G2/M phase transition points
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by cyclins and CDKs (Webster, 1998; Canavese et al., 2012).
This regulation is linked to environmental conditions as cell
contact inhibition (high cell density) and lack of growth
factors (serum deprivation) as applied here.
There is the obvious need for growing cells to coordinate
cell proliferation and apoptosis. Thus, antiapoptotic signals
frequently support cell proliferation, as reported for some Bcl-
2 proteins (Maddika et al., 2007; Danial, 2008; Plötz and
Eberle, 2014). The present data suggest enhanced TRAIL
sensitivity as a result of cell cycle inhibition. In fact, the
degree of cell cycle arrest clearly correlated with enhanced
TRAIL sensitivity.
Also, several previously reported strategies for TRAIL
sensitization induced cell cycle arrest e.g., inhibition of ion
channels or BRAF resulted in G1 arrest (Quast et al., 2012;
Berger et al., 2014), whereas an I-κB kinase inhibitor and the
natural compound indirubin resulted in G2 arrest (Berger
et al., 2011; 2013). Cell cycle arrest therefore appears as the
common end path of the different strategies leading to TRAIL
sensitization. Enhanced TRAIL sensitivity thus appears as less
dependent on a speciﬁc pathway but results from cell cycle
inhibition in general. This explains why so many different
strategies were successful, and it may open improved
perspectives for TRAIL-based therapy. Of course, used
strategies as particularly serum starvation are highly compex,
and different factors in the serum may contribute. Never-
theless, the parallel ﬁndings obtained by different strategies
strongly support the hypothesis.
Cell cycle inhibition was associated with ROS production.
As demonstrated in previous work, ROS represent a distinct
proapoptotic pathway in melanoma cells, independent of
caspases and independent of the control by Bcl-2 (Franke
et al., 2010; Quast et al., 2013). ROS may also inhibit cell
proliferation, which was related to upregulation of p21 and
Chk1 (Boonstra and Post, 2004; Verbon et al., 2012). ROS
production signiﬁcantly contributed to TRAIL sensitivity,
proven by ROS scavenging.
Second, mitochondrial proapoptotic activation seen by loss
of mitochondrial membrane potential was characteristic for
TRAIL sensitization. These pathways are controlled by pro-
and antiapoptotic Bcl-2 proteins. According to present
models, Bax and Bak drive the release of proapoptotic
mitochondrial factors into the cyctosol. They are neutralized
through heterodimerization by antiapoptotic Bcl-2 proteins
(e.g., Bcl-2, Bcl-xL, and Mcl-1), which themselves are
neutralized by BH3-only proteins (e.g., Bim and Puma;
Willis and Adams, 2005). Decisive roles of Bcl-2 and Bax
for death ligand sensitivity of melanoma cells were shown by
Bcl-2 overexpression, which prevented sensitivity (Raisova
et al., 2001; Quast et al., 2014), and by Bax activation through
different inhibitors, which enhanced TRAIL sensitivity (Quast
et al., 2012; Berger et al., 2013; Quast et al., 2013; Berger
et al., 2014). Also in the present setting, Bcl-2 and Bax played
decisive roles. Of note, loss of mitochondrial membrane
potential, ROS production, and Bax activation appeared as
early steps, which were clearly distinguished from secondary
effects in course of apoptosis, further underlining the causal
relation.
Bim and Puma are central representatives of the subgroup
of BH3-only proteins, as they can antagonize all antiapoptotic
Bcl-2 proteins (Willis and Adams, 2005; Plötz et al., 2013).
Bim is lacking in melanoma, and its re-expression has a role
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in apoptosis upon BRAF inhibition (Beck et al., 2013; Berger
et al., 2013; Plötz et al., 2013). Also, Puma expression is
reduced in metastatic melanoma as compared with primary
tumors, which may partly explain chemoresistance and p53
insensitivity (Karst et al., 2005). Puma upregulation was seen
here at HD conditions, and its signiﬁcance for TRAIL
sensitivity was proven by siRNA.
Bcl-xS, the proapoptotic alternative splice variant of Bcl-xL,
may contribute to apoptosis regulation in melanoma cells and
triggers apoptosis via Bak (Hossini and Eberle, 2008; Plötz
et al., 2012). Upregulation of Bcl-xS in course of cell cycle
arrest suggests that both the Bax- and Bak-dependent
proapoptotic pathways were activated.
In conclusion, we aimed to deﬁne common principles of
melanoma sensitization for the death ligand TRAIL. The data
clearly highlighted the importance of cell cycle arrest, which
appears as the common end path of multiple strategies.
Production of ROS as well as activation of mitochondrial
proapoptotic pathways and of Bcl-2 proteins appear as critical
downstream steps. The resulting question concerned the
mechanistic link between cell cycle arrest and proapoptotic
activation. Here, CDKs are highly suitable candidates, and
indeed TRAIL sensitivity could be similarly enhanced by CDK
4/6 inhibition.
CDKs already represent promising targets in cancer
therapy, and clinical trials are underway (Canavese et al.,
2012). As for melanoma, xenograft growth was reduced by
CDK inhibition, and early-stage trials have been initiated with
selective CDK4/6 inhibitors (Rizzolio et al., 2010; Kwong
et al., 2012; Miller and Flaherty, 2014). Tumor stasis and
cellular senescence were reported in melanoma cells,
whereas there was little evidence for direct induction of
apoptosis (Miller and Flaherty, 2014). This limits the potential
use as monotherapy, and combinations appear as necessary.
The efﬁcacy of combining CDK inhibitors with a direct
proapoptotic effector as TRAIL is demonstrated here.
MATERIALS AND METHODS
Cell culture
Human melanoma cell lines enclosed TRAIL-sensitive (A-375, SK-
Mel-13, and Mel-HO) and intrinsically TRAIL-resistant cells (Mel-2a
and MeWo; Kurbanov et al., 2005). Sublines with induced TRAIL
resistance (SK-Mel-13-TS and A-375-TS) derived from selection with
TRAIL (Kurbanov et al., 2007). Other A-375 subclones were stably
transfected with a pIRES-Bcl-2 plasmid for Bcl-2 overexpression
(A-375-Bcl-2) or with pIRES mock plasmid (A-375-Mock; Raisova
et al., 2001). Cells were cultured at 37 °C, 5% CO2 in DMEM
(4.5 g l− 1 glucose; GIBCO, Invitrogen, Karlsruhe, Germany),
supplemented with 10% FCS and antibiotics (Biochrom, Berlin,
Germany). TRAIL-selected cells were continuously kept with
5 ngml−1 TRAIL until 24 hours before treatment.
For low (normal) cell density (LD), 5× 104 and 2× 105 cells were
seeded in 24- and 6-well plates, respectively, whereas for high cell
density (HD) 2× 105 and 8× 105 cells were seeded, respectively.
For serum starvation, the growth medium was exchanged by
serum-free DMEM at 24 hours after seeding. Treatment with TRAIL
(Alexis, Gruenberg, Germany, ALX-201-073-C020, 20 ngml−1)
started 24 hours later. For CDK4/6 inhibition, PD-0332991 (Active
Biochemicals, Bonn, Germany) was applied at 2 μM at 24 hours
before TRAIL. For inhibition of apoptosis, the pancaspase inhibitor
Q-VD-OPh (MP Biomedicals, Santa Ana, CA) was used at 10 μM,
2 hours before TRAIL.
Cell cycle analysis, apoptosis, and cytotoxicity
Cell cycle analyses and quantiﬁcation of apoptosis were performed
according to Riccardi and Nicoletti (2006). Trypsinized cells were
stained with propidium iodide (Sigma-Aldrich, Taufkirchen,
Germany; 200mgml− 1, 1 hour), and cell fractions in G1, G2,
S-phase, and sub-G1 were quantiﬁed by ﬂow cytometry (FACS
Calibur, BD Bioscience, Bedford, MA). Sub-G1 cell fractions
correspond to cells with fragmented DNA (apoptotic). Cytotoxicity
was determined by measuring L-lactate dehydrogenase activity in
cell supernatants, applying a cytotoxicity detection assay (Roche
Diagnostics, Penzberg, Germany).
Mitochondrial membrane potential and ROS
Mitochondrial membrane potential (Δψm) was determined with the
ﬂuorescent dye TMRM+ (Sigma-Aldrich; 1 mM). Cells were harvested
by trypsinization, stained for 15minutes at 37 °C, and analyzed in
phosphate-buffered saline by ﬂow cytometry. For intracellular ROS,
attached cells were stained with the ﬂuorescent dye CM-H2DCFDA
(Life Technologies, Fisher Scientiﬁc, Waltham, MA; 500 μM) at
2 hours before TRAIL treatment started. Trypsinized cells in
phosphate-buffered saline were then analyzed by ﬂow cytometry.
As positive control, cells were treated with H2O2 (1 mM, 1 hour). For
ROS scavenging, N-acetylcysteine (Sigma-Aldrich; 800 μM) was
applied at 2 hours before TRAIL treatment started or at 6 hours
before ROS were quantiﬁed.
Expression analyses
For Western blotting, total protein extracts were obtained by cell lysis
in 150mM NaCl, 1 mM EDTA, 2mM phenylmethylsulfonyl ﬂuoride,
1mM leupeptin, 1mM pepstatin, 0.5% SDS, 0.5% NP-40, and 10mM
Tris-HCl, pH 7.5. Western blotting on nitrocellulose membranes was
performed as described previously (Eberle et al., 2003).
Primary antibodies of Cell Signaling (Danvers, MA): Cleaved
caspase-3 (9664, rabbit, 1:10,000), caspase-3 (9662, rabbit, 1:1,000),
caspase-8 (9746, mouse, 1:1,000), and caspase-9 (9502, rabbit,
1:1,000). Primary antibodies of Santa Cruz Biotech (Dallas, TX): Mcl-
1 (sc-12756, mouse, 1:200), Bcl-2 (sc-492, rabbit; 1:200), Bax (sc-
20067, mouse, 1:200), Bak (sc-832, 1:200), Bim (sc-11425, rabbit,
1:200), Bcl-x (sc-1041, rabbit, 1:200), and glyceraldehyde-3-
phosphate dehydrogenase (sc-32233, mouse, 1:1,000). Puma anti-
body was from Abcam (Cambridge, UK, ab33906, rabbit, 1:1,000).
Secondary antibodies were as follows: peroxidase-labeled goat anti-
rabbit and goat anti-mouse (Dako, Hamburg, Germany; 1:5,000).
Bax activation
For analysis of Bax conformational changes related to its activation
(Upton et al., 2007), a primary antibody speciﬁc for the Bax
N-terminal domain (Bax-NT, rabbit, Upstate, Lake Placid, NY, #06-
499) was applied in ﬂow cytometry. 105 cells were harvested by
trypsinization, ﬁxed in 4% paraformaldehyde, and incubated for
1 hour at 4 °C with Bax-NT antibody (1:1,000) in phosphate-buffered
saline/1% FCS/0.1% saponin (for cell permeabilization). After
incubation with the secondary antibody (goat anti-rabbit IgG
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(H+L)-FITC; Jackson Immuno Research, Newmarket, Suffolk, UK),
washing, and resuspension in phosphate-buffered saline/1% FCS,
cells were measured by ﬂow cytometry.
siRNA transfection
Transient cell transfection with siRNA was performed in six-well
plates at 24 hours after seeding; TRAIL treatment started after another
24 hours. Per 24-well, 20 pmol siRNA+4 μl TurboFect (Fermentas, St
Leon-Rot, Germany) were used. The siRNAs for Mcl-1 (sc-35877),
Puma (sc-37153), and a scrambled control (sc-37007) derived from
Santa Cruz Biotech. Another siRNA for Puma (#12845) derived from
Cell Signaling.
Statistical analyses
At least two independent experiments were performed, each
consisting of triplicates. Mean values and SDs were calculated by
enclosing all individual values (at least 6 values). Statistical
signiﬁcance was proven by Student’s t-test (normal distribution),
and P-values of o0.05 were considered as statistically signiﬁcant.
Statistical correlation coefﬁcients were calculated according to
Pearson.
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